Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Fineline Cube Feb 11, 2026
Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Fineline Cube Feb 11, 2026
Company Deals

Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China

Fineline Cube Feb 10, 2026
Company Deals

Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Fineline Cube Feb 11, 2026
Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Fineline Cube Feb 11, 2026
Company Drug

Zhaoke Ophthalmology’s Cyclosporine Eye Gel NDA Accepted by NMPA

Fineline Cube May 21, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced that the New Drug Application (NDA) for its...

Company Medical Device

Johnson & Johnson MedTech Completes First PFA Surgeries with VARIPULSE Catheter in China

Fineline Cube May 21, 2025

US-based Johnson & Johnson MedTech announced the completion of the first batch of pulse electric...

Company Deals

Shanghai CureGene Completes Series B+ Financing to Advance CG-0255 Study

Fineline Cube May 21, 2025

China-based Shanghai CureGene Pharmaceutical Co., Ltd announced the completion of a Series B+ financing round,...

Company Deals

Regeneron Wins Auction for 23andMe’s Core Business Units

Fineline Cube May 21, 2025

US-based biopharma Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced this week that it has successfully bid...

Company Drug

GSK’s Blenrep Receives Marketing Approval in Japan for Multiple Myeloma

Fineline Cube May 21, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that it has received marketing approval from...

Company Deals

Accurate Biotechnology Secures RMB 100M in Series B Funding for Organoid Technology

Fineline Cube May 21, 2025

Accurate Biotechnology, a Guangzhou-based biotech focused on organoid technology, reportedly raised RMB 100 million (USD...

Company Drug

Hainan Shuangcheng’s Generic Eptifibatide Gains TGA Marketing Approval in Australia

Fineline Cube May 21, 2025

China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has received marketing approval from Australia’s Therapeutic...

Company Medical Device

Stryker’s OptaBlate BVN System Gains FDA 510(k) Clearance

Fineline Cube May 21, 2025

US-based Stryker (NYSE: SYK) announced this week that its OptaBlate Basivertebral Nerve Ablation (BVN) system...

Company Deals

Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis

Fineline Cube May 21, 2025

Sino-US biotech Sirius Therapeutics has entered into a partnership with Swiss–American biotech CRISPR Therapeutics (NASDAQ:...

Company Drug

Zai Lab’s ZL-1310 Receives FDA Fast Track Designation for SCLC

Fineline Cube May 21, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that it has received Fast...

Company Deals

Porton and Hualong Biological Partner to Advance MATC Therapy

Fineline Cube May 21, 2025

Suzhou-based contract development and manufacturing organization (CDMO) Porton Pharma Solutions Ltd. has entered into a...

Company Drug

AB Science Secures Chinese Patent for Masitinib in COVID-19 Treatment

Fineline Cube May 20, 2025

France-based AB Science SA (EPA: AB) reported receiving patent protection in China for its lead...

Company Drug

4B Technologies Gains NMPA Approval for ALS Drug 4B02-01 Clinical Trials

Fineline Cube May 20, 2025

China-based 4B Technologies Investments Ltd has announced that it has received clinical trial approval from...

Company Deals

Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China

Fineline Cube May 20, 2025

US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with...

Company Drug

Bayer’s Jivi Receives FDA Approval for Pediatric Hemophilia A Treatment

Fineline Cube May 20, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced this week that it has received an...

Company

Alibaba Health Reports Strong 2025 Financial Results with Revenue Hike

Fineline Cube May 20, 2025

China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2025 financial report for the...

Company Drug

CSPC Pharmaceutical’s CPO301 Receives Third FDA Fast Track Designation for NSqNSCLC

Fineline Cube May 20, 2025

China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its EGFR-targeted antibody-drug conjugate (ADC) CPO301...

Company Drug

Merck Sharp & Dohme Initiates Phase III Trial of Ifinatamab Deruxtecan for Esophageal Cancer

Fineline Cube May 20, 2025

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced the first patient dosing in...

Company Deals

Terumo Corporation Acquires WuXi Biologics’ Germany Plant for EUR 150 Million

Fineline Cube May 19, 2025

Japan-based Terumo Corporation (TYO: 4543) has entered into an agreement with China-based Contract Research, Development...

Company

Grand Pharma’s Chengdu RDC Megafactory Secures Class A Radiation Safety License

Fineline Cube May 19, 2025

Grand Pharmaceutical Group Limited (HKG: 0512) has obtained a Class A Radiation Safety License from...

Posts pagination

1 … 116 117 118 … 622

Recent updates

  • China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million
  • Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial
  • Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder
  • Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device
  • Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.